GSK Requesting Re-Issuance Of Advair Patent
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline will apply to the Patent & Trademark Office for re-issuance of an Advair patent that expires in September 2010, the company's second quarter earnings release says
You may also be interested in...
Will Third Time Be Charm For Lovenox Patent Re-issuance? Aventis Considers Options
Aventis will continue to pursue re-issuance of its '618 Lovenox patent despite a second rejection letter from the Patent & Trademark Office. The firm has not decided whether to appeal the decision or present further evidence.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?